Repository logo

Browsing by Author "Hellings, PW"

Now showing 1 - 4 of 4
  • ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
    Publication . Bousquet, J; Hellings, PW; Agache, I; Bedbrook, A; Bachert, C; Bergmann, KC; Bewick, M; Bindslev-Jensen, C; Bosnic-Anticevitch, S; Bucca, C; Caimmi, DP; Camargos, PAM; Canonica, G W; Casale, T; Chavannes, NH; Cruz, AA; De Carlo, G; Dahl, R; Demoly, P; Devillier, P; Fonseca, J; Fokkens, WJ; Guldemond, NA; Haahtela, T; Illario, M; Just, J; Keil, T; Klimek, L; Kuna, P; Larenas-Linnemann, D; Morais-Almeida, M; Mullol, J; Murray, R; Naclerio, R; O'Hehir, RE; Papadopoulos, NG; Pawankar, R; Potter, P; Ryan, D; Samolinski, B; Schunemann, HJ; Sheikh, A; Simons, FER; Stellato, C; Todo-Bom, A; Tomazic, PV; Valiulis, A; Valovirta, E; Ventura, MT; Wickman, M; Young, I; Yorgancioglu, A; Zuberbier, T; Aberer, W; Akdis, CA; Akdis, M; Annesi-Maesano, I; Ankri, J; Ansotegui, IJ; Anto, JM; Arnavielhe, S; Asarnoj, A; Arshad, H; Avolio, F; Baiardini, I; Barbara, C; Barbagallo, M; Bateman, D; Beghé, B; Bel, EH; Bennoor, KS; Benson, M; Białoszewski, AZ; Bieber, T; Bjermer, L; Blain, H; Blasi, F; Boner, L; Bonini, M; Bonini, S; Bosse, I; Bouchard, J; Boulet, LP; Bourret, R; Bousquet, PJ; Braido, F; Briggs, AH; Brightling, CE; Brozek, J; Buhl, R; Bunu, C; Burte, E; Bush, A; Caballero-Fonseca, F; Calderon, MA; Camuzat, T; Cardona, V; Carreiro-Martins, P; Carriazo, AM; Carlsen, K H; Carr, W; Cepeda Sarabia, AM; Cesari, M; Chatzi, L; Chiron, R; Chivato, T; Chkhartishvili, E; Chuchalin, AG; Chung, KF; Ciprandi, G; Correia de Sousa, J; Cox, L; Crooks, G; Custovic, A; Dahlen, SE; Darsow, U; Dedeu, T; Deleanu, D; Denburg, JA; De Vries, G; Didier, A; Dinh-Xuan, AT; Dokic, D; Douagui, H; Dray, G; Dubakiene, R; Durham, SR; Du Toit, G; Dykewicz, MS; Eklund, P; El-Gamal, Y; Ellers, E; Emuzyte, R; Farrell, J; Fink Wagner, A; Fiocchi, A; Fletcher, M; Forastiere, F; Gaga, M; Gamkrelidze, A; Gemicioğlu, B; Gereda, J E; van Wick, RG; González Diaz, S; Grisle, I; Grouse, L; Gutter, Z; Guzmán, MA; Hellquist-Dahl, B; Heinrich, J; Horak, F; Hourihane, JOB; Humbert, M; Hyland, M; Iaccarino, G; Jares, EJ; Jeandel, C; Johnston, SL; Joos, G; Jonquet, O; Jung, KS; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Kalyoncu, A F; Kardas, P; Keith, PK; Kerkhof, M; Kerstjens, HAM; Khaltaev, N; Kogevinas, M; Kolek, V; Koppelman, GH; Kowalski, ML; Kuitunen, M; Kull, I; Kvedariene, V; Lambrecht, B; Lau, S; Laune, D; Le, LTT; Lieberman, P; Lipworth, B; Li, J; Lodrup Carlsen, KC; Louis, R; Lupinek, C; MacNee, W; Magar, Y; Magnan, A; Mahboub, B; Maier, D; Majer, I; Malva, J; Manning, P; De Manuel Keenoy, E; Marshall, GD; Masjedi, MR; Mathieu-Dupas, E; Maurer, M; Mavale-Manuel, S; Melén, E; Melo-Gomes, E; Meltzer, EO; Mercier, J; Merk, H; Miculinic, N; Mihaltan, F; Milenkovic, B; Millot-Keurinck, J; Mohammad, Y; Momas, I; Mösges, R; Muraro, A; Namazova-Baranova, L; Nadif, R; Neffen, H; Nekam, K; Nieto, A; Niggemann, B; Nogueira-Silva, L; Nogues, M; Nyembue, TD; Ohta, K; Okamoto, Y; Okubo, K; Olive-Elias, M; Ouedraogo, S; Paggiaro, P; Pali-Schöll, I; Palkonen, S; Panzner, P; Papi, A; Park, HS; Passalacqua, G; Pedersen, S; Pereira, AM; Pfaar, O; Picard, R; Pigearias, B; Pin, I; Plavec, D; Pohl, W; Popov, TA; Portejoie, F; Postma, D; Poulsen, LK; Price, D; Rabe, KF; Raciborski, F; Roberts, G; Robalo-Cordeiro, C; Rodenas, F; Rodriguez-Mañas, L; Rolland, C; Roman Rodriguez, M; Romano, A; Rosado-Pinto, J; Rosario, N; Rottem, M; Sanchez-Borges, M; Sastre-Dominguez, J; Scadding, GK; Scichilone, N; Schmid-Grendelmeier, P; Serrano, E; Shields, M; Siroux, V; Sisul, JC; Skrindo, I; Smit, HA; Solé, D; Sooronbaev, T; Spranger, O; Stelmach, R; Sterk, PJ; Strandberg, T; Sunyer, J; Thijs, C; Triggiani, M; Valenta, R; Valero, A; van Eerd, M; van Ganse, E; van Hague, M; Vandenplas, O; Varona, LL; Vellas, B; Vezzani, G; Vazankari, T; Viegi, G; Vontetsianos, T; Wagenmann, M; Walker, S; Wang, DY; Wahn, U; Werfel, T; Whalley, B; Williams, DM; Williams, S; Wilson, N; Wright, J; Yawn, BP; Yiallouros, PK; Yusuf, OM; Zaidi, A; Zar, HJ; Zernotti, ME; Zhang, L; Zhong, N; Zidarn, M
    The Allergic Rhinitis and its Impact on Asthma (ARIA) initiative commenced during a World Health Organization workshop in 1999. The initial goals were (1) to propose a new allergic rhinitis classification, (2) to promote the concept of multi-morbidity in asthma and rhinitis and (3) to develop guidelines with all stakeholders that could be used globally for all countries and populations. ARIA-disseminated and implemented in over 70 countries globally-is now focusing on the implementation of emerging technologies for individualized and predictive medicine. MASK [MACVIA (Contre les Maladies Chroniques pour un Vieillissement Actif)-ARIA Sentinel NetworK] uses mobile technology to develop care pathways for the management of rhinitis and asthma by a multi-disciplinary group and by patients themselves. An app (Android and iOS) is available in 20 countries and 15 languages. It uses a visual analogue scale to assess symptom control and work productivity as well as a clinical decision support system. It is associated with an inter-operable tablet for physicians and other health care professionals. The scaling up strategy uses the recommendations of the European Innovation Partnership on Active and Healthy Ageing. The aim of the novel ARIA approach is to provide an active and healthy life to rhinitis sufferers, whatever their age, sex or socio-economic status, in order to reduce health and social inequalities incurred by the disease.
    2016Journal article Open access Show more
  • Next-Generation Allergic Rhinitis and Its Impact on Asthma (ARIA) Guidelines for Allergic Rhinitis Based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and Real-World Evidence
    Publication . Bousquet, J; Schünemann, HJ; Togias, A; Bachert, C; Erhola, M; Hellings, PW; Klimek, L; Pfaar, O; Wallace, D; Ansotegui, I; Agache, I; Walker, S; Waserman, S; Yorgancioglu, A; Zuberbier, T; Bedbrook, A; Bergmann, KC; Bewick, M; Bonniaud, P; Bosnic-Anticevich, S; Bossé, I; Bouchard, J; Boulet, LP; Brozek, J; Brusselle, G; Calderon, MA; Canonica, WG; Caraballo, L; Cardona, V; Casale, T; Cecchi, L; Chu, DK; Costa, EM; Cruz, AA; Czarlewski, W; D'Amato, G; Devillier, P; Dykewicz, M; Ebisawa, M; Fauquert, JL; Fokkens, WJ; Fonseca, JA; Fontaine, JF; Gemicioglu, B; van Wijk, RG; Haahtela, T; Halken, S; Ierodiakonou, D; Iinuma, T; Ivancevich, JC; Jutel, M; Kaidashev, I; Khaitov, M; Kalayci, O; Kleine Tebbe, J; Kowalski, ML; Kuna, P; Kvedariene, V; La Grutta, S; Larenas-Linnemann, D; Lau, S; Laune, D; Le, L; Lieberman, P; Lodrup Carlsen, KC; Lourenço, O; Marien, G; Carreiro-Martins, P; Melén, E; Menditto, E; Neffen, H; Mercier, G; Mosgues, R; Mullol, J; Muraro, A; Namazova, L; Novellino, E; O'Hehir, R; Okamoto, Y; Ohta, K; Park, HS; Panzner, P; Passalacqua, G; Pham-Thi, N; Price, D; Roberts, G; Roche, N; Rolland, C; Rosario, N; Ryan, D; Samolinski, B; Sanchez-Borges, M; Scadding, GL; Shamji, MH; Sheikh, A; Todo Bom, AM; Toppila-Salmi, S; Tsiligianni, I; Valentin-Rostan, M; Valiulis, A; Valovirta, E; Ventura, MT
    The selection of pharmacotherapy for patients with allergic rhinitis aims to control the disease and depends on many factors. Grading of Recommendations Assessment, Development and Evaluation (GRADE) guidelines have considerably improved the treatment of allergic rhinitis. However, there is an increasing trend toward use of real-world evidence to inform clinical practice, especially because randomized controlled trials are often limited with regard to the applicability of results. The Contre les Maladies Chroniques pour un Vieillissement Actif (MACVIA) algorithm has proposed an allergic rhinitis treatment by a consensus group. This simple algorithm can be used to step up or step down allergic rhinitis treatment. Next-generation guidelines for the pharmacologic treatment of allergic rhinitis were developed by using existing GRADE-based guidelines for the disease, real-world evidence provided by mobile technology, and additive studies (allergen chamber studies) to refine the MACVIA algorithm.
    2020Journal article Open access Show more
  • Pilot Study of Mobile Phone Technology in Allergic Rhinitis in European Countries: the MASK-Rhinitis Study
    Publication . Bousquet, J; Caimmi, DP; Bedbrook, A; Bewick, M; Hellings, PW; Devillier, P; Arnavielhe, S; Bachert, C; Bergmann, KC; Canonica, GW; Chavannes, NH; Cruz, AA; Dahl, R; Demoly, P; De Vries, G; Mathieu-Dupas, E; Finkwagner, A; Fonseca, J; Guldemond, N; Haahtela, T; Hellqvist-Dahl, B; Just, J; Keil, T; Klimek, L; Kowalski, ML; Kuitunen, M; Kuna, P; Kvedariene, V; Laune, D; Pereira, AM; Carreiro-Martins, P; Melén, E; Morais-Almeida, M; Mullol, J; Muraro, A; Murray, R; Nogueira-Silva, L; Papadopoulos, NG; Passalacqua, G; Portejoie, F; Price, D; Ryan, D; Samolinski, B; Sheikh, A; Siroux, V; Spranger, O; Todo Bom, A; Tomazic, PV; Valero, A; Valovirta, E; Valiulis, A; VandenPlas, O; van der Meulen, S; van Eerd, M; Wickman, M; Zuberbier, T
    The use of Apps running on smartphones and tablets profoundly affects medicine. The MASK-rhinitis (MACVIA-ARIA Sentinel NetworK for allergic rhinitis) App (Allergy Diary) assesses allergic rhinitis symptoms, disease control and impact on patients' lives. It is freely available in 20 countries (iOS and Android platforms). AIMS: To assess in a pilot study whether (i) Allergy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characteristics based upon data captured by the Allergy Diary could be identified and (iii) information gathered by this study could suggest novel research questions. METHODS: The Allergy Diary users were classified into six groups according to the baseline data that they entered into the App: (i) asymptomatic; (ii) nasal symptoms excluding rhinorrhea; (iii) rhinorrhea; (iv) rhinorrhea plus 1-2 nasal/ocular symptoms; (v) rhinorrhea plus ≥3 nasal/ocular symptoms; and (vi) rhinorrhea plus all nasal/ocular symptoms. RESULTS: By 1 June 2016, 3260 users had registered with the Allergy Diary and 2710 had completed the baseline questionnaire. Troublesome symptoms were found mainly in the users with the most symptoms. Around 50% of users with troublesome rhinitis and/or ocular symptoms suffered work impairment. Sleep was impaired by troublesome symptoms and nasal obstruction. CONCLUSIONS: This is the first App (iOS and Android) to have tested for allergic rhinitis and conjunctivitis. A simple questionnaire administered by cell phones enables the identification of phenotypic differences between a priori defined rhinitis groups. The results suggest novel concepts and research questions in allergic rhinitis that may not be identified using classical methods
    2017-06Journal article Open access Show more
  • Treatment of Allergic Rhinitis Using Mobile Technology with Real-World Data: the MASK Observational Pilot Study
    Publication . Bousquet, J; Devillier, P; Arnavielhe, S; Bedbrook, A; Alexis-Alexandre, G; van Eerd, M; Murray, R; Canonica, GW; Illario, M; Menditto, E; Passalacqua, G; Stellato, C; Triggiani, M; Carreiro-Martins, P; Fonseca, J; Morais Almeida, M; Nogueira-Silva, L; Pereira, AM; Todo Bom, A; Bosse, I; Caimmi, D; Demoly, P; Fontaine, JF; Just, J; Onorato, G L; Kowalski, ML; Kuna, P; Samolinski, B; Anto, JM; Mullol, J; Valero, A; Tomazic, PV; Bergmann, KC; Keil, T; Klimek, L; Mösges, R; Shamai, S; Zuberbier, T; Murphy, E; McDowall, P; Price, D; Ryan, D; Sheikh, A; Chavannes, NH; Fokkens, W J; Kvedariene, V; Valiulis, A; Bachert, C; Hellings, PW; Kull, I; Melen, E; Wickman, M; Bindslev-Jensen, C; Eller, E; Haahtela, T; Papadopoulos, NG; Annesi-Maesano, I; Bewick, M; Bosnic-Anticevich, S; Cruz, A A; De Vries, G; Gemicioglu, B; Larenas-Linnemann, D; Laune, D; Mathieu-Dupas, E; O'Hehir, RE; Pfaar, O; Portejoie, F; Siroux, V; Spranger, O; Valovirta, E; VandenPlas, O; Yorgancioglu, A
    Background: Large observational implementation studies are needed to triangulate the findings from randomized control trials as they reflect "real-world" everyday practice. In a pilot study, we attempted to provide additional and complementary insights on the real-life treatment of allergic rhinitis (AR) using mobile technology. Methods: A mobile phone app (Allergy Diary, freely available in Google Play and Apple App stores) collects the data of daily visual analog scales (VAS) for (i) overall allergic symptoms, (ii) nasal, ocular, and asthma symptoms, (iii) work, as well as (iv) medication use using a treatment scroll list including all medications (prescribed and over the counter (OTC)) for rhinitis customized for 15 countries. Results: A total of 2871 users filled in 17 091 days of VAS in 2015 and 2016. Medications were reported for 9634 days. The assessment of days appeared to be more informative than the course of the treatment as, in real life, patients do not necessarily use treatment on a daily basis; rather, they appear to increase treatment use with the loss of symptom control. The Allergy Diary allowed differentiation between treatments within or between classes (intranasal corticosteroid use containing medications and oral H1-antihistamines). The control of days differed between no [best control], single, or multiple treatments (worst control). Conclusions: This study confirms the usefulness of the Allergy Diary in accessing and assessing everyday use and practice in AR. This pilot observational study uses a very simple assessment (VAS) on a mobile phone, shows novel findings, and generates new hypotheses.
    2018Journal article Open access Show more